Supplements

← vista completa

Published on December 1, 2010 | http://doi.org/10.5867/medwave.2010.11.4808

Current evidence on the combination of a direct renin inhibitor and an ARB or ACE inhibitor

Evidencia actual de la combinación de un IDR y un ARA II/IECA

Javier Díez

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Javier Díez

Facultad de Medicina, Universidad de Navarra. Pamplona, España.

Figures

Article has no figures.

Forum

No messages

History

Citation Díez J. Current evidence on the combination of a direct renin inhibitor and an ARB or ACE inhibitor. Medwave 2010;10(11):e4808 doi: 10.5867/medwave.2010.11.4808

Publication date 01/12/2010

Index

Article metrics

Article has no metrics.

Notes

References

  1. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 Jul 21;370(9583):221-9. | CrossRef | PubMed
  2. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8. | CrossRef | PubMed
  3. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 Jun 5;358(23):2433-46. | CrossRef | PubMed
  4. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17-24. | CrossRef | PubMed
  5. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 Feb 3;119(4):530-7. Epub 2009 Jan 19. | CrossRef | PubMed
  6. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006 Mar;1(2):221-8. Epub 2005 Dec 22. | CrossRef | PubMed
  7. Ferrario CM. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci. 2010 Feb 27;86(9-10):289-99. Epub 2009 Dec 1. | CrossRef | PubMed
  8. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008 Dec;57(12):3297-306. Epub 2008 Oct 1. | CrossRef | PubMed
  9. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept. 2004 Aug 15;120(1-3):5-13. | CrossRef | PubMed